The Biopharmaceutical Classification System (BCS) guidance issued by the FDA allows waivers for in vivo bioavailability and bioequivalence studies for immediate-release (IR) solid oral dosage forms only for BCS class I drugs. However, a number of drugs within BCS class III have been proposed to be eligible for biowaivers. The World Health Organization (WHO) has shortened the requisite dissolution time of BCS class III drugs on their Essential Medicine List (EML) from 30 to 15 min for extended biowaivers; however, the impact of the shorter dissolution time on AUC 0−inf and C max is unknown. The objectives of this investigation were to assess the ability of gastrointestinal simulation software to predict the oral absorption of the BCS class I drugs propranolol and metoprolol and the BCS class III drugs cimetidine, atenolol, and amoxicillin, and to perform in silico bioequivalence studies to assess the feasibility of extending biowaivers to BCS class III drugs. The drug absorption from the gastrointestinal tract was predicted using physicochemical and pharmacokinetic properties of test drugs provided by GastroPlus (version 6.0). Virtual trials with a 200 mL dose volume at different drug release rates ( T 85% = 15 to 180 min) were performed to predict the oral absorption ( C max and AUC 0−inf) of the above drugs. Both BCS class I drugs satisfied bioequivalence with regard to the release rates up to 120 min. Class III High solubility Low intestinal permeability Class IV Low solubility Low intestinal permeability BCS classification – cont’d 6 Early in development, in vitro solubility and in vitro permeability studies are conducted to obtain preliminary BCS classification. FDA has issued a final guidance entitled Waiver of In-vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. The Biowaiver Extension for BCS Class III Drugs: The Effect of Dissolution Rate on the Bioequivalence of BCS Class III Immediate-Release Drugs Predicted by Computer Simulation. SUPPORT OF THE ELIGIBILITY OF A DRUG PRODUCT FOR A BCS-BASED. A drug product is eligible for a BCS-based biowaiver provid that the drug substance(s) ed. Satisfy the criteria regarding solubility and permeability (BCS Class I and III), the drug. Bcs Class 1 DrugsThe results with BCS class III drugs demonstrated bioequivalence using the prolonged release rate, T 85% = 45 or 60 min, indicating that the dissolution standard for bioequivalence is dependent on the intestinal membrane permeability and permeability profile throughout the gastrointestinal tract. The results of GastroPlus simulations indicate that the dissolution rate of BCS class III drugs could be prolonged to the point where dissolution, rather than permeability, would control the overall absorption. For BCS class III drugs with intestinal absorption patterns similar to those of cimetidine, atenolol or amoxicillin, the dissolution criteria for extension of biowaivers to BCS class III drugs warrants further investigation. • Ca' Foscari University of Venice • Cagliari State University • Free University of Bolzano • Politecnico di Bari • Scuola Superiore Sant'Anna • University of Bologna • University of Camerino • University of Genoa • University of Messina • University of Naples Federico II • University of Padova • University of Palermo • University of Parma • University of Pavia • University of Perugia • University of Pisa • University of Roma TRE • University of Rome Tor Vergata • University of Siena • University of Verona. • Agilent Technologies Inc • Agnes Scott College • Ajman University of Science and Technology • AkzoNobel • Aligarh Muslim University • Anonymous Petcare • Aston University • Azusa Pacific (APU) & Los Angeles Pacific (LAPU) University • BP International • BRAC University • Bar-Ilan University • Baylor Health Sciences Library • Birkbeck College • Bridgend College • Bristol-Myers Squibb • Calico Life Sciences LLC • Case Western Reserve University • Celgene • Columbus State University • Coventry University • DSM N.V. • Defence Science and Technology Group (DST) • Delaware Valley University • Deutsches Zentrum fur Neurodegenerative Erkrankungen • East Tennessee State Universi. The oral route is the first envisaged route when developing a novel pharmaceutical entity since it is conducive to promoting treatment compliance. However, this route is being abandoned for numerous molecules under development on account of their low oral bioavailability. This may be due to various factors related to the very properties of the molecules or to the physiology of the gastrointestinal tract (Fasinu, et al., 2011). Various approaches have been investigated over the last ten years to improve the oral bioavailability of these molecules including physical or chemical means. The BCS classification of molecules (Biopharmaceutics Classification System) is a significant tool used for the development of oral forms in the pharmaceutical industry and has been adopted in particular by the FDA, EMEA and WHO (Dahan, et al., 2009). This system is divided into four categories of molecules and is based on the fundamental elements which control oral absorption i.e. Intestinal membrane permeability and the solubility of a molecule in the gastrointestinal medium. A molecule is considered soluble if the maximum dose of an immediate-release form is soluble in 250 ml or less of an aqueous medium having a pH of between 1.2 and 6.8, and is considered permeable if its absorption through the intestinal membrane is 90% or higher. A BCS molecule belonging to class III is highly soluble and scarcely permeable. Program parkir vb 6.0. This latter characteristic is the factor limiting oral bioavailability and may lead to abandoning the development of an oral formulation of molecules nevertheless having strong therapeutic potential. At usual therapeutic doses, baclofen is known to have good oral bioavailability. Yet its low log P indicates some hydrophilicity and hence low permeability. This observation can be accounted for by the presence of specific transporters at the small intestine allowing the molecule to pass. The transport of the molecule is greater at the jejunum. Therefore low transport at the colon would indicate the presence of another transport mechanism through the intestinal barrier (Merino, et al., 1989). This region of the digestive system does not contain any transporters but since the molecule is hydrophilic and of small size, some passive transport through the tight junctions is possible. It therefore appears that when a higher plasma concentration of baclofen is desired, the taking of a higher dose is not efficient on account of saturation of the transporters. The clinical solution applied is to take smaller doses at closer time intervals which may soon become burdensome for the patient. An increase in the lipophilicity of baclofen and thereby its transcellular permeability was observed when producing prodrugs of baclofen ester (Leisen, et al., 2003). Through these properties a greater concentration of prodrug was found at the target tissue i.e. The brain due to easier crossing of the blood brain barrier. However, greater affinity for the efflux pump P-gp is to be noted as well as partial hydrolysis of the prodrug to baclofen which finally leads to a lower level of baclofen at the site of action after administration of the prodrug compared with administration of baclofen alone. Bcs Class Iii 2017A baclofen absorption window was evidenced at the small intestine due to the presence of transporters (Merino, et al., 1989). To increase bioavailability, this absorption window could be used to advantage for pharmaceutical techniques allowing the retaining of the oral form at or upstream of the window (Davis, 2005). A longer residence time at the absorption site should theoretically allow more extensive movement of molecules across the intestinal barrier if they are not likely to undergo pre-systemic degradation before being absorbed. Therefore, bioadhesive forms adhering to the intestinal mucus through the use of cationic polymers such as chitosan, or gastro-retaining forms allowing the swelling and floating of the form in the stomach have been developed in recent years in the pharmaceutical sector but their efficacy is highly dependent on intra- and interindividual variability. Under normal physiological conditions, the paracellular pathway takes up less than 0.1% of the total surface area of the intestinal epithelium, and it is therefore not a major pathway (Anilkumar, et al., 2001). This can be attributed to the presence of tight junctions between the cells which limits the absorption of molecules of size greater than 0.1 nm. Therefore action on the latter could allow a significant increase in absorption. The tight junctions play a barrier role between the components of the apical and basolateral domains, and are composed of various protein complexes involved in the regulation of the integrity of the junctions (zonula occludens, actin, claudin-1,.. This integrity is modified by confrontation with various physiological and pathological agents and in particular by secondary messengers originating from the signalling pathways. Two factors appear to be involved in the face of action by absorption enhancers: the contraction an actin-myosin ring and phosphorylation by kinase and phosphatase proteins. Anilkumar et al. Listed the absorption enhancers that are the subject of research for this indication. Bcs Class Iii RankingsBcs Class Ii DrugThese include surfactants, biliary acids and derivatives, fatty acids and derivatives, chelating agents, chitosan and the derivatives thereof, and the polycarbophylcysteine conjugate. The Caco-2 cells are derived from the culture of human cells of cancerous origin capable of differentiating in the presence of a suitable culture medium (Pontier, 1997-1998). Their properties are a function of the number of subcultures to which they are subjected.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |